Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 13/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 13/20 | 0.36 |
| ▸ | CA2 | P00918 | 6/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22012078 | 0.87 | ASIC3 (0.34) | ASIC3PRMT5WDR77 | |
| SCHEMBL21962438 | 0.81 | PRMT5 (0.32) | ASIC3PRMT5WDR77 | |
| SCHEMBL22012769 | 0.79 | PRMT5 (0.36) | PRMT5WDR77 | |
| SCHEMBL25796836 | 0.78 | CA2 (0.35) | PRMT5WDR77CA2 | |
| SCHEMBL22012077 | 0.77 | PRMT5 (0.34) | PRMT5WDR77 | |
| SCHEMBL22012071 | 0.76 | PNMT (0.38) | ASIC3PRMT5WDR77 | |
| SCHEMBL22012770 | 0.71 | PRMT5 (0.37) | ASIC3PRMT5WDR77 | |
| SCHEMBL10649011 | 0.69 | DRD2 (0.40) | CA2 | |
| SCHEMBL21962432 | 0.68 | ALDH1A1 (0.51) | ASIC3PRMT5WDR77 | |
| SCHEMBL21962422 | 0.68 | NR1H2 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-16 | — | — | US | disclosed |
| WO-2020102576-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | ASIC3 996/4885PRMT5 3244/4885WDR77 809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.